Top

Archives of Osteoporosis

Published in:

01-12-2019 | Bisphosphonate | Original Article

Management of osteoporosis in the Middle East and North Africa: a survey of physicians’ perceptions and practices

Authors: Salem A. Beshyah, Yousef Al-Saleh, Ghada El-Hajj Fuleihan

Published in: Archives of Osteoporosis | Issue 1/2019

Abstract

Summary

We surveyed 573 physicians in the Middle East regarding osteoporosis management. Sixty percent had access to, but were not in charge of, densitometry reporting. Screening for secondary causes was common; 62% were aware of FRAX®; less than half used it. Medications were accessible, and most participants had concerns regarding bisphosphonates. Barriers to care were identified.

Introduction

The 2011 IOF Middle East Osteoporosis Audit highlighted major care gaps in osteoporosis care in the Middle East and North Africa (MENA) region. We investigated osteoporosis management practice patterns in this region.

Methods

We mailed an electronic survey to a convenience sample of physicians, explaining the study rationale and methods. It gathered information on physicians’ profiles, availability and utilization of resources, risk assessment, and management.

Results

Five hundred seventy-three responses were obtained from the United Arab Emirates (UAE, 36%), Saudi Arabia (KSA, 25%), Lebanon (14%), and others (25%). Endocrinology was the single most represented specialty. Sixty percent of participants had access to densitometers, but treating physicians were not in charge of densitometry reading. Screening for vitamin D deficiency and secondary contributors to osteoporosis was frequently implemented. Although two-thirds of professionals were aware of FRAX®, only 42% used it, either because of lack of know how or of a country specific calculator. Almost all (96.0%) had access to oral and 68.9% to intravenous bisphosphonates, and over half to teriparatide (46.4%) and denosumab (45.0%). Most participants (92%) were aware of concerns regarding side effects of bisphosphonates, and this changed the management in the majority (73%). Important barriers to osteoporosis care were lack of osteoporosis awareness among physicians, patients, and cost of treatment.

Conclusions

This first look at physicians’ practice patterns on the diagnosis and treatment of osteoporosis in the MENA region underscores the pressing need for an official call for action, at all levels, to address this large care gap.

Available only for authorised users

Eastell R, O'Neill TW, Hofbauer LC, Langdahl B, Reid IR, Gold DT, Cummings SR (2016) Postmenopausal osteoporosis. Nat Rev Dis Primers 2:16069CrossRefPubMed

El-Hajj Fuleihan G, Adib G, Nauroy L (2011) The Middle East and Africa regional audit: epidemiology, costs & burden of osteoporosis in 2011. International Osteoporosis Foundation Available from: https://www.iofbonehealth.org. Accessed 23 May 2019

Khosla S, Cauley JA, Compston J, Kiel DP, Rosen C, Saag KG, Shane E (2017) Addressing the crisis in the treatment of osteoporosis: a path forward. J Bone Miner Res 32(3):424–430. https://doi.org/10.1002/jbmr.3074 CrossRefPubMed

Eisman JA, Bogoch ER, Dell R, Harrington JT, McKinney RE Jr, McLellan A, Mitchell PJ, Silverman S, Singleton R, Siris E (2012) ASBMR task force on secondary fracture prevention. Making the first fracture the last fracture: ASBMR task force report on secondary fracture prevention. J Bone Miner Res 27(10):2039–2046. https://doi.org/10.1002/jbmr.1698 CrossRefPubMed

Kanis JA, Johansson H, Oden A, Cooper C, Mccloskey EV (2014) Epidemiology and quality of life working group of IOF. Arch Osteoporos 9(1):166. https://doi.org/10.1007/s11657-013-0166-8. CrossRefPubMed

Cosman F, de Beur SJ, LeBoff MS, Lewiecki EM, Tanner B, Randall S, Lindsay R, National Osteoporosis Foundation (2014) Clinician’s guide to prevention and treatment of osteoporosis. Osteoporos Int 25(10):2359–2381. https://doi.org/10.1007/s00198-014-2794-2 CrossRefPubMedPubMedCentral

Kanis JA, Hans D, Cooper C, Baim S, Bilezikian JP, Binkley N, Cauley JA, Compston JE, Dawson-Hughes B, El-Hajj Fuleihan G, Johansson H, Leslie WD, Lewiecki EM, Luckey M, Oden A, Papapoulos SE, Poiana C, Rizzoli R, Wahl DA, McCloskey EV, Task Force of the FRAX Initiative (2011) Interpretation and use of FRAX in clinical practice. Osteoporos Int 22(9):2395–2411CrossRefPubMed

Gel-H F, Bouillon R, Clarke B, Chakhtoura M, Cooper C, McClung M, Singh RJ (2015) Serum 25-hydroxyvitamin D levels: variability, knowledge gaps, and the concept of a desirable range. J Bone Miner Res 30(7):1119–1133. https://doi.org/10.1002/jbmr.2536 CrossRef

Hoteit M, Al-Shaar L, Yazbeck C, Bou Sleiman M, Ghalayini T, Fuleihan G-H (2014) Hypovitaminosis D in a sunny country: time trends, predictors, and implications for practice guidelines. Metabolism 63(7):968–978. https://doi.org/10.1016/j.metabol.2014.04.009 CrossRefPubMed

10.

Bassil D, Rahme M, Hoteit M, Fuleihan G-H (2013) Hypovitaminosis D in the Middle East and North Africa: prevalence, risk factors and impact on outcomes. Dermatoendocrinol 5(2):274–298CrossRefPubMedPubMedCentral

11.

Adler A, El-Hajj Fuleihan G, Bauer D, Camacho P, Clarke B, Clines G, Compston J, Drake M, Edwards B, Favus M, Greenspan S, McKinnet R Jr, Pingolo R, Sellmeyer D (2016) Managing osteoporosis in patients on long-term bisphophonate treatment. Report of a task force of the American Society for Bone and Mineral Research. JBMR 31(1):16–35CrossRef

12.

Beshyah SA, Khalil AB, Sherif IH, Benbarka MM, Raza SA, Hussein W, Alzahrani AS, Chadli A (2017) A survey of clinical practice patterns in management of graves disease in the Middle East and North Africa. Endocr Pract 23(3):299–308CrossRefPubMed

13.

Beshyah SA, Sherif IH, Chentli F, Hamrahian A, Khalil AB, Raef H, el-Fikki M, Jambart S (2017) Management of prolactinomas: a survey of physicians from the Middle East and North Africa. Pituitary 20(2):231–240CrossRefPubMed

14.

Korthoewer D, Chandran M (2012) Osteoporosis management and the utilization of FRAX®: a survey amongst health care professionals of the Asia Pacific. Arch Osteoporosis 7(1–2):193–200CrossRef

15.

Ha YC, Lee YK, Lim YT, Jang SM, Shin CS (2014) Physicians’ attitudes to contemporary issues on osteoporosis management in Korea. J Bone Metab 21:143–149CrossRefPubMedPubMedCentral

16.

Al-Saleh Y, Sulimani R, Sabico S et al (2015) Guidelines for osteoporosis in Saudi Arabia: recommendations from the Saudi Osteoporosis Society. Ann Saudi Med 35:1–12CrossRefPubMedPubMedCentral

17.

Chakhtoura M, Leslie WD, McClung M, Cheung AM, Fuleihan GE (2017) The FRAX-based Lebanese osteoporosis treatment guidelines: rationale for a hybrid model. Osteoporos Int 28(1):127–137CrossRefPubMed

18.

American Association of Clinical Endocrinologists (2010) Medical guidelines for clinical practice for the diagnosis and treatment of postmenopausal osteoporosis. Endocr Pract 16(suppl 3):1–37

19.

Eastell R, Rosen CJ, Black DM, Cheung AM, Murad MH, Shoback D (2019) Pharmacological management of osteoporosis in postmenopausal women: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 104(5):1595–1622. https://doi.org/10.1210/jc.2019-00221 CrossRefPubMed

20.

Alwahhabi BK (2015) Osteoporosis in Saudi Arabia. Are we doing enough? Saudi Med J 36(10):1149–1150CrossRefPubMedPubMedCentral

21.

Sadat-Ali M, Al-Dakheel DA, Azam MQ, Al-Bluwi MT, Al-Farhan MF, AlAmer HA et al (2015) Reassessment of osteoporosis-related femoral fractures and economic burden in Saudi Arabia. Arch Osteoporos 10:37. https://doi.org/10.1007/s11657-015-0240-5 CrossRefPubMed

22.

Bubshait D, Sadat-Ali M (2007) Economic implications of osteoporosis-related femoral fractures in Saudi Arabian society. Calcif Tissue Int 81(6):455–458CrossRefPubMed

23.

Beshyah SA, Al Mehri W, Khalil AB (2013) Osteoporosis and its management: an exploratory study of the knowledge, attitudes and practices of physicians working in the United Arab Emirates. Ibnosina J Med BS 5(5):270–279CrossRef

24.

Elliot-Gibson V, Bogoch ER, Jamal SA et al (2004) Practice patterns in the diagnosis and treatment of osteoporosis after a fragility fracture: a systematic review. Osteoporosis Int 15(10):767–778CrossRef

25.

Lewiecki EM, Baim S, Binkley N et al (2008) Report of the International Society for Clinical Densitometry 2007 adult position development conference and official positions. South Med J 101:735–739CrossRefPubMed

26.

Cadarette S, Gignac M, Jaglal S et al (2007) Access to osteoporosis treatment is critically linked to access to dual-energy X-ray absorptiometry testing. Med Care 45(9):896–901CrossRefPubMed

27.

Chami G, Jeys L, Freudmann M, Connor L, Siddiqi M (2006) Are osteoporotic fractures being adequately investigated? A questionnaire of GP & orthopaedic surgeons. BMC Fam Pract 7:7CrossRefPubMedPubMedCentral

28.

Hans D, Kanis J, Baim S, Bilezikian JP, Binkley N, Cauley JA, Compston JE, Cooper C, Dawson-Hughes B, el-Hajj Fuleihan G, Leslie WD, Lewiecki EM, Luckey MM, McCloskey E, Papapoulos SE, Poiana C, Rizzoli R, FRAX(®) Position Development Conference Members (2011) Joint official positions of the International Society for Clinical Densitometry and International Osteoporosis Foundation on FRAX((R)). Executive summary of the 2010 position development conference on interpretation and use of FRAX(R) in clinical practice. J Clin Densitom 14(3):171–180CrossRefPubMed

29.

Johansson H, Kanis JA, Oden A, Johnell O, McCloskey E (2009) BMD, clinical risk factors and their combination for hip fracture prevention. Osteoporos Int 20:1675–1682CrossRefPubMed

30.

El-Hajj Fuleihan G, Chakhtoura M, Cauley JA, Chamoun N (2017) Worldwide Fracture Prediction. J Clin Densitom 20(3):397–424. https://doi.org/10.1016/j.jocd.2017.06.008 CrossRefPubMed

31.

Cauley JA, El-Hajj Fuleihan G, Arabi A (2011) FRAX(®) position conference members. Official positions for FRAX® clinical regarding international differences from joint official positions development conference of the International Society for Clinical Densitometry and International Osteoporosis Foundation on FRAX®. J Clin Densitom 14(3):240–262CrossRefPubMed

32.

Lips P, Cashman KD, Lamberg-Allardt C, et al. (2019) Management of endocrine disease: Current vitamin D status in European and Middle East countries and strategies to prevent vitamin D deficiency; a position statement of the European calcified tissue society. Eur J Endocrinol 180(4):P23–P54. https://doi.org/10.1530/EJE-18-0736

33.

Nowson CA (2010) Prevention of fractures in older people with calcium and vitamin D. Nutrients 2:975–984CrossRefPubMedPubMedCentral

34.

Rosen CJ, Gallagher JC (2011) The 2011 IOM report on vitamin D and calcium requirements for North America: clinical implications for providers treating patients with low bone mineral density. J Clin Densitom 14(2):79–84CrossRefPubMed

35.

Holick MF, Binkley NC, Bischoff-Ferrari HA, Gordon CM, Hanley DA, Heaney RP, Murad MH, Weaver CM, Endocrine Society (2011l) Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 96(7):1911–1930CrossRefPubMed

36.

Cesareo R, Attanasio R, Caputo M et al (2018) Italian Association of Clinical Endocrinologists (AME) and Italian Chapter of the American Association of Clinical Endocrinologists (AACE) Position Statement: Clinical Management of Vitamin D Deficiency in Adults. Nutrients 10(5)

37.

Schilcher J, Michaelsson K, Aspenberg P (2011) Bisphosphonate use and atypical fractures of the femoral shaft. N Engl J Med 364:1728–1737

38.

National institute for health and clinical excellence (NICE). Alendronate, etidronate, risedronate, raloxifene, strontium ranelate and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women (amended). NICE technology appraisal guidance 161 (amended). National Institute for Health and Clinical Excellence (NICE), London; 2011.

39.

Simonelli C, Killeen K, Mehle S, Swanson L (2002) Barriers to osteoporosis identification and treatment among primary care physicians and orthopedic surgeons. Mayo Clin Proc 77(4):334–338CrossRefPubMed

Title: Management of osteoporosis in the Middle East and North Africa: a survey of physicians’ perceptions and practices
Authors: Salem A. Beshyah
Yousef Al-Saleh
Ghada El-Hajj Fuleihan
Publication date: 01-12-2019
Publisher: Springer London
Keywords: Bisphosphonate
Care
Osteoporosis
Osteoporosis
Published in: Archives of Osteoporosis / Issue 1/2019
Print ISSN: 1862-3522
Electronic ISSN: 1862-3514
DOI: https://doi.org/10.1007/s11657-019-0609-y

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Management of osteoporosis in the Middle East and North Africa: a survey of physicians’ perceptions and practices

Abstract

Summary

Introduction

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Summary

Introduction

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2019

The effects of short-term back extensor strength training in postmenopausal osteoporotic women with vertebral fractures: comparison of supervised and home exercise program

Temporal changes in access to FRAX® in Thailand between 2010 and 2018

Osteoporosis preventive behaviors in adolescent girls: the educational program based on BASNEF model

Celiac disease and severe vitamin D deficiency: the case for anti-tissue transglutaminase antibody screening

Correction to: Effect of periodic abstinence from dairy products for approximately half of the year on bone health in adults following the Christian Orthodox Church fasting rules for decades

An unusual Chinese case of celiac disease presenting as hypocalcemia and low bone density